Computer-based strategy for modeling the interaction of AGRP and related peptide ligands with the AGRP-binding site of murine melanocortin receptors

Current Pharmaceutical Design

Volumn 11, Issue 3, 2005, Pages 345-356

  Wang, Xiang ^a   Richards, Nigel G J ^a  

^a University of Florida   (United States)

Author keywords

AGRP; Cyclic peptide; G protein coupled receptor; Homology model; Membrane mimetic; Murine melanocortin receptors; Receptor bound conformation

Indexed keywords

AGOUTI RELATED PROTEIN; ANTIOBESITY AGENT; APPETITE STIMULANT; HISTIDINYLPHENYLALANYLARGINYLTRYPTOPHAN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MUTANT PROTEIN; PEPTOID; UNCLASSIFIED DRUG;

ANOREXIA; BINDING SITE; COMPLEX FORMATION; COMPUTER MODEL; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EATING DISORDER; FEEDING BEHAVIOR; HUMAN; HYPOTHESIS; MODULATION; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; BINDING SITES; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MICE; PROTEINS; RECEPTOR, MELANOCORTIN, TYPE 4; TECHNOLOGY, PHARMACEUTICAL;

EID: 14044262913     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382188     Document Type: Review

References (154)

1. Abdel-Malek ZA. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001; 58: 434-441.
2. Goodfellow VS, Saunders, J. The melanocortin system and its role in obesity and cachexia. Curr Top Med Chem 2003; 3: 855-883.
3. Prusis P, Schioth HB, Muceniece R, Herzyk P, Afshar M, Hubbard RE, et al. Modeling of the three-dimensional structure of the human melanocortin 1 receptor, using an automated method and docking of a rigid cyclic melanocyte-stimulating hormone core peptide. J Mol Graph Model 1997; 15: 307-317.
4. Prusis P, Frandberg P-A, Muceniece R, Kalvinsh I, Wikberg JES. A 3-dimensional model for the interaction of MSH with the melanocortin-1 receptor. Biochem Biophys Res Commun 1995; 210: 205-210.
5. Yang X, Wang Z, Dong W, Ling L, Yang H, Chen R. Modeling and docking of the three-dimensional structure of the human melanocortin 4 receptor. J Prot Chem 2003; 22: 335-344.
6. Cone, RD, Lu DS, Koppula S, Vage DI, Klungland H, Boston B, et al. The melanocortin receptors: Agonists, antagonists, and the hormonal control of pigmentation. Recent Progr Hormone Res 1996; 51: 287-318.
7. Lu DS, Willard D, Patel IR, Kadwell S, Overton L, Kost T, et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371: 799-802.
8. Chhajlani V, Wikberg JES. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett 1992; 309: 417-420.
9. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, et al. Molecular cloning of a novel melanocortin receptor. J. Biol Chem 1993; 268: 8246-8250.
10. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro, T, Watson DJ, et al. Molecular cloning, expression, and gene localization of a 4th melanocortin receptor. J. Biol Chem 1993; 268: 15174-15179.
11. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T. Molecular cloning, expression, and characterization of a 5th melanocortin receptor. Biochem Biophys Res Commun 1994; 200: 1214-1220.
12. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in the neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8: 1298-1308.
13. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992; 257: 1248-1251.
14. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, et al. Identification of a receptor for gamma-melanocortin and other proopiomelano-cortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993; 90: 8856-8860.
15. Hruby VJ, Wilkes BC, Cody WL, Sawyer TK, Hadley ME. Melanotropins: Structural, conformational, and biological considerations in the development of superpotent and superprolonged analogs. Pept Prot Rev 1984; 3: 1-64.
16. Lu DS, Väge DI, Cone RD. A ligand-mimetic model for constitutive activation of the melanocortin-1 receptor. Mol Endocrinol 1998; 12: 592-604.
17. Butler AA, Cone RD. Knockout studies defining different roles for melanocortin receptors in energy homeostasis. Ann NY Acad Sci 2003; 994: 240-245.
18. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26: 97-102.
19. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141: 3518-3521.
20. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
21. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997; 91: 789-798.
22. Chhajlani V, Muceniece R, Wikberg JES. Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun 1993; 195: 866-873.
23. Starowicz K, Przewlocka B. The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception. Life Sci 2003; 73: 823-847.
24. Zimanyi IA, Pelleymounter MA. The role of melanocortin peptides and receptors in regulation of energy balance. Curr Pharm Des 2003; 9: 627-641.
25. Haskell-Luevano C, Sawyer TK, Hendrata S, North C, Panahinia L, Stum M, et al. Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity. Peptides 1996; 17: 995-1002.
26. Hruby VJ, Wilkes BC, Hadley ME, Al-Obeidi F, Sawyer TK, Staples DJ, et al. Alpha-melanotrophin: The minimal active sequence in the frog skin assay. J Med Chem 1987; 30: 2126-2130.
27. Holder JR, Bauzo RM, Xiang ZM, Scott J, Haskell-Luevano C. Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence. J Med Chem 2003; 13: 4505-4509.
28. Miller MW, Duhl DMJ, Vrieling H, Cordes SP, Ollmann, MM, Winkes BM, et al. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal-yellow mutation. Genes Dev 1993; 7: 454-467.
29. Ollmann MM, Wilson BD, Yang Y-K, Kerns JA, Chen Y, Gantz I, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135-138.
30. Mizuno TM, Makimura H, Mobbs CV. The physiological function of the agouti-related peptide gene: the control of weight and metabolic rate. Ann Med 2003; 35: 425-433.
31. Adan RAH, Kas MJH. Inverse agonism gains weight. Trends Pharmacol Sci 2003; 24: 315-321.
32. Dinulescu DM, Cone RD. Agouti and agouti-related protein: Analogies and contrasts. J Biol Chem 2000; 275: 6695-6698.
33. Yang YK, Thompson DA, Dickinson CJ, Wilken J, Barsh GS, Kent SBH, et al. Characterization of agouti-related protein binding to melanocortin receptors. Mol. Endocrinol 1999; 13: 148-155.
34. 2 fragment is a potent inhibitor of melanocortin receptor function. FEBS Lett 1998; 428: 59-62.
35. Perry WL, Nakamura T, Swing DA, Secrest L, Eagleson B, Hustad CM, et al. Coupled site-directed mutagenesis/transgenesis identifies important functional domains of the mouse agouti protein. Genetics 1996; 144: 255-264.
36. Perry WL, Hustad CM, Swing DA, Jenkins NA, Copeland NG. A transgenic mouse assay for agouti protein activity. Genetics 1995; 140: 267-274.
37. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, et al. Agouti structure and function - Characterization of a potent alpha-melanocyte-stimulating hormone-receptor antagonist. Biochemistry 1995; 34: 12341-12346.
38. Kiefer LL, Ittoop ORR, Bunce K, Truesdale AT, Willard DH, Nichols JS, et al. Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors. Biochemistry 1997; 36: 2084-2090.
39. Kiefer LL, Veal JM, Mountjoy KG, Wilkison WO. Melanocortin receptor binding determinants in the agouti protein. Biochemistry 1998; 37: 991-997.
40. McNulty JC, Thompson DA, Bolin KA, Wilken J, Barsh GS, Millhauser GL. High-resolution NMR structure of the chemically-synthesized melanocortin receptor binding domain AGRP(87-132) of the agouti-related protein. Biochemistry 2001; 40: 15520-15527.
41. Bolin KA, Anderson DJ, Trulson JA, Thompson DA, Wilken J, Kent SB, et al. NMR structure of a minimized human agouti-related protein prepared by chemical synthesis. FEBS Lett 1999; 451: 125-131.
42. Bures EJ, Hui JO, Young, Y, Chow DT, Katta V, Rohde MF, et al. Determination of disulfide structure in agouti-related protein (AGRP) by stepwise reduction and alkylation. Biochemistry 1998; 37: 12172-12177.
43. Craik DJ, Daly NL, Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001; 39: 43-60.
44. Ponting CP, Russell RR. The natural history of protein domains. Annu Rev Biophys Biomol Struct 2002; 31: 45-71.
45. Narashiman L, Singh J, Humblet C, Guruprasad K, Blundell T. Snail and spider toxins share a similar tertiary structure and cysteine motif. Nat Struct Biol 1994; 1: 850-852.
46. Miles LA, Dy CY, Nielsen J, Barnham KJ, Hinds MG, Olivera BM, et al. Structure of a novel P-superfamily spasmodic conotoxin reveals an inhibitory cystine knot. J Biol Chem 2002; 277: 43033-43040.
47. Haskell-Luevano C, Sawyer TK, Trumpp-Kallmeyer S, Bikker JA, Humblet C, Gantz I, et al. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Drug Des Discov 1996; 14:197-211.
48. Luecke H, Schobert B, Richter HT, Cartailler JP, Lanyi JK. Structure of bacteriorhodopsin at 1.55 angstrom resolution. J Mol Biol 1999; 291: 899-911.
49. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001; 40: 7761-7772.
50. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-745.
51. Filipek S, Teller DC, Palczewski K, Stenkamp R. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 2003; 32: 375-397.
52. Scaramellini C, Leff P. Theoretical implications of receptor coupling to multiple G proteins based on analysis of a three-state model. Methods Enzymol 2002; 343: 17-29.
53. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995; 25: 366-428.
54. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. EMBO J 1993; 12: 1693-1703.
55. Baldwin JM, Schertler GFX, Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G protein-coupled receptors. J Mol Biol 1997; 272: 144-164.
56. Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, et al. Functional microdomains in G-protein-coupled receptors: The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 1998; 273: 10445-10453.
57. Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, Weinstein H. Structural motifs as functional microdomains in G protein-coupled receptors: Energetic considerations in the mechanism of activation of the serotonin 5-HT2A receptor by disruption of the ionic lock of the arginine cage. Int J Quantum Chem 2002; 88: 65-75,
58. Visiers I, Ballesteros JA, Weinstein H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 2002; 343: 329-371.
59. Govaerts, C, Lefort A, Costagliola S, Wodak SJ, Ballesteros JA, Van Sande J, et al. A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. J Biol Chem 2001; 276: 22991-22999.
60. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SGF, Shi L, Gether U, et al. Activation of the beta(2)-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001; 276: 29171-29177.
61. 2A receptor. J Biol Chem 1995; 270: 16683-16688.
62. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001; 60: 1-19.
63. Javitch JA, Shi L, Simpson MM, Chen J, Chiappa V, Visiers I, et al. The fourth transmembrane segment of the dopamine D2 receptor: Accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 2000; 39: 12190-12199.
64. Brooks BR, Cheatham, TE. Recent advances in molecular dynamics simulation towards the realistic representation of biomolecules in solution. Theor Chem Acc 1998; 99: 279-288.
65. Brooks CL III, Karplus M, Pettit BM. Proteins: A theoretical perspective of dynamics, structure and thermodynamics. Adv Chem Phys 1988; 71: 1-259.
66. Kirkpatrick S, Delatt CD Jr, Vecchi MP. Optimization by simulated annealing. Science 1983; 220: 671-680.
67. Brunger AT, Adams PD, Rice LM. Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr Op Struct Biol 1998; 8: 600-611.
68. Ji TH, Grossmann M, Ji IH. G protein-coupled receptors I. Diversity of receptor-ligand interactions. J Biol Chem 1998; 273: 17299-17302.
69. Holst B, Zoffmann S, Elling CE, Hjorth SA, Schwartz TW. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Mol Pharmacol 1998; 53: 166-175.
70. Alla SA, Quitterer U, Grigoriev S, Maidhof A, Haasemann M, Jarnagin K, et al. Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J Biol Chem 1996; 271: 1748-1755.
71. Mehler EL, Periole X, Hassan SA, Weinstein H. Key issues in the computational simulation of GPCR function: representation of loop domains. J Comput-Aided Mol Des 2002; 16: 841-853.
72. Sankararamakrishnan R, Konvicka K, Mehler EL, Weinstein H. Solvation in simulated annealing and high-temperature molecular dynamics of proteins: A restrained water droplet model. Int J Quantum Chem 2000; 77: 174-185.
73. Schioth HB, Lagerstrom MC, Watanabe H, Jonsson L, Vergoni AV, Ringholm A, et al. Functional role, structure, and evolution of the melanocortin-4 receptor. Ann NY Acad Sci 2003; 994: 74-83.
74. Nickolls SA, Cismowski MI, Wang XC, Wolff M, Conlon PJ, Maki RA. Molecular determinants of melanocortin-4 receptor ligand binding and MC4/MC3 receptor selectivity. J Pharm Exp Therapeut 2003; 304: 1217-1227.
75. Yang YK, Chen M, Lai, YM, Gantz I, Georgeson KE, Harmon CM. Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selectivity. J Biol Chem 2002; 277: 20328-20335.
76. Haskell-Luevano C, Cone RD, Monck EK, Wan Y-P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: Identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 2001; 40: 6164-6179.
77. Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 2000; 39: 14900-14911.
78. Yang YK, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle(4), D-Phe(7)]melanocyte-stimulating hormone with the melanocortin-1 receptor (melanocyte alpha-MSH receptor). J Biol Chem 1997; 272: 23000-23010.
79. Chhajlani V, Xu X, Blauw J, Sudarshi S. Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. Biochem Biophys Res Commun 1996; 219: 521-525.
80. Schioth HB, Muceniece R, Szardenings M, Prusis P, Wikberg JES. Evidence indicating that the TM4, EL2, and TM5 of the melanocortin-3 receptor do not participate in ligand binding. Biochem Biophys Res Commun 1996; 229: 687-692.
81. Yang Y, Chen M, Lai YM, Gantz I, Yagmurlu A, Georgeson KE, et al. Molecular determination of agouti-related protein binding to human melanocortin-4 receptor. Mol Pharmacol 2003; 64: 94-103.
82. Yang YK, Dickinson CJ, Zeng Q, Li JY, Thompson DK, Gantz I. Contribution of melanocortin receptor exoloops to agouti-related protein binding. J Biol Chem 1999; 274: 14100-14106.
83. Jackson PJ, McNulty JC, Yang YK, Thompson DA, Chai BX, Gantz I, et al. Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. Biochemistry 2002; 41: 7565-7572.
84. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucl Acids Res 2000; 28: 235-242.
85. Tota MR, Smith TS, Mao C, MacNeil T, Mosley RT, Van der Ploeg LHT, et al. Molecular interaction of agouti and agouti-related protein with human melanocortin receptors. Biochemistry 1999; 38: 897-904.
86. Zhang DQ, Weinstein H. Signal transduction by a 5-HT2 receptor: A mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. J Med Chem 1993; 36: 934-938.
87. Gershengorn M, Osman R. Insights into G protein-coupled receptor function using molecular models. Endocrinology 2001; 142: 2-10.
88. Gether U, Kobilka BK. G protein-coupled receptors. II Mechanism of agonist activation. J Biol Chem 1998; 273: 17979-17982.
89. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK. Structural instability of a constitutively active G protein-coupled receptor: Agonist-independent activation due to conformational flexibility. J Biol Chem 1997; 272: 2587-2590.
90. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta(2)-adrenoceptor. EMBO J 1997; 16: 6737-6747.
91. Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, et al. Identification of putative agouti-related protein (87-132)/melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. J Med Chem 2004; 47: 2194-2207.
92. Anezo C, de Vries AH, Holtje HD, Tieleman DP, Marrink SJ. Methodological issues in lipid bilayer simulations. J Phys Chem B 2003; 107: 9424-9433.
93. Chandrasekhar I, Kastenholz M, Lins RD, Oostenbrink C, Schuler LD, Tieleman DP, et al. A consistent potential energy parameter set for lipids: Dipalmitoylphosphatidylcholine as a benchmark of the GROMOS96 force field. Eur Biophys J Biophys Lett 2003; 32: 67-77.
94. + channel. Proc Natl Acad Sci USA 2003; 100: 8644-8648.
95. + channel. Nature 2001; 414: 73-77.
96. Allen TW, Anderson OS, Roux B. Structure of gramicidin A in a lipid bilayer environment determined using molecular dynamics simulations and solid-state NMR data. J Am Chem Soc 2003; 125: 9868-9877.
97. Iadanza M, Holtje M, Ronsisvalle G, Holtje HD. Kappa-opioid receptor model in a phospholipid bilayer: Molecular dynamics simulations. J Med Chem 2002; 45: 4838-4846.
98. Zhu FQ, Tajkhorshid E, Schulten K. Theory and simulation of water permeation in aquaporin-1. Biophys J 2004; 86: 50-57.
99. Jensen MO, Tajkhorshid E, Schulten K. Electrostatic tuning of permeation and selectivity in aquaporin water channels. Biophys J 2003; 85: 2884-2889.
100. Burykin A, Warshel A. What really prevents proton transport through aquaporin? Charge self-energy versus proton wire proposals. Biophys J 2003; 85: 3696-3706.
101. de Groot BL, Frigato T, Helms, V, Grubmuller H. The mechanism of proton exclusion in the aquaporin-1 water channel. J Mol Biol 2003; 333: 279-293.
102. Tieleman DP, Leontiadou H, Mark AE, Marrink SJ. Simulation of pore formation in lipid bilayers by mechanical stress and electric fields. J Am Chem Soc 2003; 125: 6382-6383.
103. Law RJ, Tieleman DP, Sansom MSP. Pores formed by the nicotinic receptor M2 delta peptide: A molecular dynamics simulation study. Biophys J 2003; 84: 14-27.
104. Aliste MP, MacCullum JL, Tieleman DP. Molecular dynamics simulations of pentapeptides at interfaces: Salt bridge and cation-pi interactions. Biochemistry 2003; 42: 8976-8987.
105. Marrinck SJ, Tieleman DP. Molecular dynamics simulation of spontaneous membrane fusion during a cubic-hexagonal phase transition. Biophys J 2002; 83: 2386-2392.
106. Tieleman DP, Hess B, Sansom MSP. Analysis and evaluation of channel models: Simulations of alamethicin. Biophys J 2002; 83: 2393-2407.
107. Marrinck SJ, Tieleman DP, Mark AE. Molecular dynamics simulation of the kinetics of spontaneous micelle formation. J Phys Chem B 2000; 104: 12165-12173.
108. Tieleman DP, Forrest LR, Sansom MSP, Berendsen HJC. Lipid properties and the orientation of aromatic residues in OmpF, influenza M2, and alamethicin systems: Molecular dynamics simulations. Biochemistry 1998; 37: 17554-17561.
109. Tieleman DP, Marrinck SJ, Berendsen HJC. A computer perspective of membranes: Molecular dynamics studies of lipid bilayer systems. Biochim Biophys Acta 1997; 1331: 235-270.
110. Lague P, Zuckermann MJ, Roux B. Lipid-mediated interactions between intrinsic membrane proteins: Dependence on protein size and lipid composition. Biophys J 2001; 81: 276-284.
111. MacCallum JL, Tieleman DP. Structures of neat and hydrated 1-octanol from computer simulations. J Am Chem Soc 2002; 124: 15085-15093.
112. Thirumoorthy R, Holder JR, Bauzo RM, Richards NGJ, Edison AS, Haskell-Luevano C. Novel agouti-related-protein-based melano-cortin-1 receptor antagonist. J Med Chem 2001; 44: 4114-4124.
113. Haskell-Luevano C, Monck EK, Wan YP, Schentrup AM. The agouti-related protein decapeptide (Yc[CRFFNAFC]Y) possesses agonist activity at the murine melanocortin-1 receptor. Peptides 2000; 21: 683-689.
114. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, Galligan JJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward delta-opioid receptors. Proc Natl Acad Sci USA 1983; 80: 5871-5874.
115. 5]enkephalin opioid analogs. J Pharmacol Exp Therap 1993; 266: 1649-1655.
116. Williams SA, Abbruscato TJ, Hruby VJ, Davis TP. Passage of a delta-opioid receptor selective enkephalin, [D-penicillamine(2,5)]enkephalin, across the blood-brain and blood-cerebrospinal fluid barriers. J Neurochem 1996; 66: 1289-1299.
117. 2 receptor: A mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. J Med Chem 1993; 36: 934-938.
118. Strader CD, Fong TM, Underwood D, Dixon RAF. Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994; 63: 101-132.
119. Alkorta I, Loew GH. A 3D model of the delta opioid receptor and ligand-receptor complexes. Prot Engin 1996; 9: 573-583.
120. Bikker JA, Trumpp-Kallmeyer S, Humblet C. G protein-coupled receptors: Models, mutagenesis, and drug design. J Med Chem 1998; 41: 2911-2927.
121. Ijzerman AP, Van Galen PJM, Jacobson KA. Molecular modeling of adenosine receptors. 1. The ligand binding site on the A1 receptor. Drug Design Disc 1992; 9: 49-67.
122. Kamik SS, Gogonea C, Patil S, Saad Y, Takezako T. Activation of G-protein-coupled receptors: A common molecular mechanism. Trends Endocrinol Metab 2003; 14: 431-437.
123. Gether U. Uncovering the molecular mechanisms involved in activation of G protein-coupled receptors. Endocrinol Rev 2000; 21: 90-113.
124. Tieleman DP, Berendsen HJC, Sansom MSP. Voltage-dependent insertion of alamethicin at phospholipid/water and octane/water interfaces. Biophys J 2001; 80: 331-341.
125. Rolz C, Mierke DF. Characterization of the molecular motions of constitutively active G protein-coupled receptors for parathyroid hormone. Biophys J 2001; 89: 119-128.
126. Rolz C, Pellegrini M, Mierke DF. Molecular characterization of the receptor-ligand complex for parathyroid hormone. Biochemistry 1999; 38: 6397-6405.
127. van Buuren AR, Marrink SJ, Berendsen HJC. A molecular dynamics study of the decane water interface. J Phys Chem 1993; 97: 9206-9212.
128. Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001; 7: 306-317.
129. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926-935.
130. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth Particle Mesh Ewald method. Chem Phys 1995; 103: 8577-8593.
131. Darden T, York D, Pedersen L. Particle Mesh Ewald - An Nlog(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089-10092.
132. Linse P. Monte Carlo simulation of liquid-liquid benzene water interface. J Chem Phys 1987; 86: 4177-4187.
133. Carpenter IL, Hehre WJ. A molecular dynamics study of the hexane water interface. J Phys Chem 1990; 94: 531-536.
134. Rohrig UF, Guidoni L, Röthlisberger U. Early steps of the intramolecular signal transduction in rhodopsin explored by molecular dynamics simulations. Biochemistry 2002; 41: 10799-10809.
135. Shenkin PS, McDonald DQ. Cluster analysis of molecular conformations. J Comput Chem 1994; 15: 899-916.
136. van Gunsteren WF, Luque FJ, Timms D, Torda AE. Molecular mechanics in biology: From structure to function, taking account of solvation. Annu Rev Biophys Biomol Struct 1994; 23: 847-863.
137. van Gunsteren WF, Mark AE. On the interpretation of biochemical data by molecular dynamics computer simulation. Eur J Biochem 1992; 204: 947-961.
138. Dauber-Osguthorpe P, Maunder CM, Osguthorpe DJ. Molecular dynamics: Deciphering the data. J Comput-Aided Mol Des 1996; 10: 177-185.
139. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001; 41: 856-864.
140. Teague SJ, Davis AM, Leeson PD, Oprea T. The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl 1999; 38: 3743-3748.
141. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997; 23: 3-25.
142. Walters WP, Ajay; Murcko MA. Recognizing molecules with drug-like properties. Curr Op Chem Biol 1999; 3: 384-387.
143. Mazur AW, Kulesza A, Mishra RK, Cross-Doersen D, Russell AF, Ebetino FH. Novel tetrahydropyran-based peptidomimetics from a bioisosteric transformation of a tripeptide. Evidence of their activity at melanocortin receptors. Bioorg Med Chem 2003; 11: 3053-3063.
144. Hruby VJ, Balse PM. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem 2000; 7: 945-970.
145. Perez JJ, Corcho F, Llorens O. Molecular modeling in the design of peptidomimetics and peptide surrogates. Curr Med Chem 2002; 9: 2209-2229.
146. Jones RM, Boatman PD, Semple G, Shin YJ, Tamura SY. Clinically validated peptides as templates for de novo peptidomimetic drug design at G protein-coupled receptors. Curr Op Pharmacol 2003; 3: 530-543.
147. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002; 9: 646-652.
148. Bleicher KH, Böhm H-J, Müller K, Alanine AI. Hit and lead generation: Beyond high-throughput screening. Nature Drug Disc Rev 2003; 2: 369-378.
149. Humphrey W, Dalke A, Schulten K. VMD - Visual Molecular Dynamics. J Mol Graph 1996; 14: 33-38
150. Taylor JW, Kaiser ET. Structure-function analysis of proteins through the design, synthesis and study of peptide models. Methods Enzymol 1987; 154: 473-498.
151. Dunnill P. The use of helical net-diagrams to represent protein structures. Biophys J 1968; 8: 865-875.
152. Horvath TL, Castaneda T, Tang-Christensen M, Pagotto U, Tschop MH. Ghrelin as a potential anti-obesity target. Curr Pharm Design 2003; 9(17): 1383-95.
153. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Design 2003; 9(19): 1529-43.
154. Zimanyi IA, Pelleymounter MA. The role of melanocortin peptides and receptors in regulation of energy balance. Curr Pharm Design 2003; 9(8): 627-41.